Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 413-090-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Specific investigations: other studies
Administrative data
- Endpoint:
- specific investigations: other studies
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- Not specified.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non-GLP study, not conducted to any recognised guidelines, as is an investigational assessment of bioavailability. Allocated as Reliability 2 as the study is conducted by a recognised research facility, and the results are well documented.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- In mice dosed orally with the test substance, the bioavailability was determined by analysis of blood and bone marrow samples taken 4 hours and 24 hours after oral dosing with 2000 mg/kg bw and in urine samples collected over 24 h after oral dosing with 2000 mg/kg bw. The expected decomposition product Reactive Yellow F68072-vinyl (formed by hydrolysis of Reactive Yellow F68072 under aqueous conditions) was quantified by HPLC with UV-detection.
- GLP compliance:
- no
- Type of method:
- in vivo
Test material
- Reference substance name:
- lithium sodium 2-amino-4-{[4-(cyanoazanidyl)-6-[(3-sulfonatophenyl)amino]-1,3,5-triazin-2-yl]amino}-5-(2-{4-[2-(sulfonatooxy)ethanesulfonyl]phenyl}diazen-1-yl)benzene-1-sulfonate
- EC Number:
- 413-090-5
- Cas Number:
- 189574-45-6
- Molecular formula:
- Hill formula: C24H18LixN10NayO12S4
- IUPAC Name:
- lithium sodium 2-amino-4-{[4-(cyanoazanidyl)-6-[(3-sulfonatophenyl)amino]-1,3,5-triazin-2-yl]amino}-5-(2-{4-[2-(sulfonatooxy)ethanesulfonyl]phenyl}diazen-1-yl)benzene-1-sulfonate
- Test material form:
- solid: particulate/powder
- Details on test material:
- See below
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- other: Not specified.
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Male B6C3F1 mice (n - 10, aged 8-10 weeks at arrival in the animal facility of the department) were purchased from Harian-Winkelmann, Borchen, Germany. On the day of treatment (July 16, 2007), mice (n = 5, body weight range 24.1 g-33.2g). The animals had free access to water and a standard diet (T.2018 Global Rodent Breeding, Harlan Teklad, Station Road, Blackthorn, Bicester, Oxon, 0X25 1TP, United Kingdom) and were kept under standard conditions (12 h day/night cycle, temperature 21 – 23 °C, humidity 45 - 55 %) before administration.
Administration / exposure
- Route of administration:
- oral: unspecified
- Vehicle:
- not specified
- Details on exposure:
- Mice (n = 5, body weight range 24.1 g-33.2g) were orally administered Reactive Yellow F68072 at doses of 2,000 mg/kg bw in deionized water (7.5 mL/kg bw). The animals had free access to water and a standard diet (T.2Q18 Global Rodent Breeding, Harlan Teklad, Station Road, Blackthorn, Bicester, Oxon OX25 1TP, United Kingdom) and were kept under standard conditions (12 h day/night cycle, temperature 21 - 23 deg C; humidity 45 - 55 %) before administration. For blood sampling four hours after administration, mice were anaesthetized with carbon dioxide and blood samples were taken by cardiac puncture. Blood samples were kept at -20°C before sample workup. In a second experiments, mice (n = 5) were administered Reactive Yellow F68072 at doses of 2000 mg/kg bw in deionized water (7.5 mL/kg bw) and were transferred to metabolic cages to collect urine and feces immediately after administration. Animals were kept in the cages for 24 h and urine was collected at 4 deg C. After the urine collection period, animals were anaesthetized with carbon dioxide and blood samples were taken as described above.
- Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Not conducted.
- Duration of treatment / exposure:
- 24 hours
- Frequency of treatment:
- Single dose
- Post exposure period:
- None
Doses / concentrations
- Dose / conc.:
- 2 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- Sampling. Blood samples were collected in Monovettes (Sarsted, Germany). The blood samples were centrifuged for 15 min at 1.500 x g and the supernatants were stored at -20X until sample workup for analysis by HPLC. Volume of urine samples was determined and the samples were frozen immediately without further treatment. The samples were analyzed in August/September of 2007.
Sample preparation. To plasma samples, two volumes of water/ethanol (60.40, v:v) were added and the samples was extracted using ultrasound for 15 minutes at room temperature. The suspensions obtained wore then subjected to centrifugation (10 min at6,000 rpm) and the obtained supernatant (0.1 mL) was injected into the HPLC-system. Urine samples were also treated with two volumes of water:ethanol and subjected to centrifugation as described for blood samples. Bone marrow rinsed from femurs with phosphate butter was treated with 2 volumes of ethanol/water (60:40, v;v) subjected to sonication at room temperature for 15 minutes, centrifuged and 0.1 ml of the obtained supernatant were analysed by HPLC. Recovery of Remazol vinyl from spiked blood samples was > 90 %.
Analytical methods. The samples were separated on a HyperSK ODS3 HPLC column (4 ^ mm x 300 mm; 5///n; Maisch, Ammerbuch, Germany) using an Agilent 1090 HPLC-pump coupled to a diode array detector (Agilent, Waldbronn, Germany}. Separation was performed by gradient elution with 50 mM potassium phosphate buffer (solvent A) and methanol (solvent B) using the following conditions: linear gradient from 5 % b to 60% B within 35 min at a flow-rate of 1 ml/min. The UV-absorption of the eluate from the column was monitored at 248 and 440 nm. Calibration standards containing known concentrations of Reactive Yellow F68072-vinyl were prepared in water at pH 7 and five concentrations were used to generate calibration curves. Relative standard deviations were < 10 % on repeated injections.
Examinations
- Examinations:
- As detailed above.
- Positive control:
- None
Results and discussion
- Details on results:
- Concentrations of Reactive Yellow F68072-vinyl in the 24-hour urine samples was 320 µg/mL at 248 nm.
In blood samples collected 4 hours after oral administration of Reactive Yellow F68072, concentrations of Reactive Yellow F68072-vinyl were very low and close to the limit of detection. However, all samples contained a small peak co-eluting with the authentic Reactive Yellow F68072-vinyl standards at 24.9 minutes. Concentrations of Reactive Yellow F68072-vinyl in the samples collected 4 hours after substance administration was 9.53 µg/mL at 248 nm. In blood samples taken 24 hours after Reactive Yellow F68072 administration, concentrations of Reactive Yellow F68072-vinyl were below the limit of detection in all samples.
Any other information on results incl. tables
When analyzing Reactive Yellow F68072-vinyl standards, the compound gave two peaks in the HPLC separation with similar UV-spectra eluting at app. 24.9 min.
In urine from mice receiving 2000 mg Reactive Yellow F68072/kg bw, samples collected for 24 hours after administration contained the typical peaks for Reactive Yellow F68072-vinyl, which were characterised by recorded electronic spectra and the relative intensities of the signals recorded at 248 and 440 nm at the expected retention time of 24.9 minutes. Concentrations of Reactive Yellow F68072-vinyl in the 24-hour urine samples was 320 µg/mL at 248 nm.
In blood samples collected 4 hours after oral administration of Reactive Yellow F68072, concentrations of Reactive Yellow F68072-vinyl were very low and close to the limit of detection. However, all samples contained a small peak co-eluting with the authentic Reactive Yellow F68072-vinyl standards at 24.9 minutes. Concentrations of Reactive Yellow F68072-vinyl in the samples collected 4 hours after substance administration was 9.53 µg/mL at 248 nm. In blood samples taken 24 hours after Reactive Yellow F68072 administration, concentrations of Reactive Yellow F68072-vinyl were below the limit of detection in all samples.
Conclusions
The demonstration of the presence of Reactive Yellow F68072-vinyl in urine samples from mice given Reactive Yellow F68072 shows that orally administered Reactive Yellow F68072 is bioavailable. Gastrointestinal absorption of Reactive Yellow F68072 results in a translocation of the compound to blood after passing the liver and the highly water soluble Reactive Yellow F68072-vinyl is then translocated to the kidney to be excreted, in part, with urine. Absorption of Reactive Yellow F68072 from the gastrointestinal tract is also supported by the detection of Reactive Yellow F68072-vinyl in blood, although the concentrations present at the 4-hour sampling point selected for analysis were low.
Applicant's summary and conclusion
- Conclusions:
- The demonstration of the presence of Reactive Yellow F68072-vinyl in urine samples from mice given Reactive Yellow F68072 shows that orally administered Reactive Yellow F68072 is bioavailable. Gastrointestinal absorption of Reactive Yellow F68072 results in a translocation of the compound to blood after passing the liver and the highly water soluble Reactive Yellow F68072-vinyl is then translocated to the kidney to be excreted, in part, with urine. Absorption of Reactive Yellow F68072 from the gastrointestinal tract is also supported by the detection of Reactive Yellow F68072-vinyl in blood, although the concentrations present at the 4-hour sampling point selected for analysis were low.
- Executive summary:
This study addresses the bioavailability of Reactive Yellow F68072 after oral administration in mice to support the conclusions on absence of genotoxicity in vivo based on a negative in vivo micronucleus test in mice performed by Hoechst AG. To assess bioavailability, concentrations of the decomposition product Reactive Yellow F68072-vinyl, which is formed from Reactive Yellow F68072 in aqueous solutions at pH 7, were determined in blood and urine samples from mice dosed orally with Reactive Yellow F68072 in water.
The demonstration of the presence of Reactive Yellow F68072-vinyl in urine samples from mice given Reactive Yellow F68072 shows that orally administered Reactive Yellow F68072 is bioavailable. Gastrointestinal absorption of Reactive Yellow F68072 results in a translocation of the compound to blood after passing the liver and the highly water soluble Reactive Yellow F68072-vinyl is then translocated to the kidney to be excreted, in part, with urine. Absorption of Reactive Yellow F68072 from the gastrointestinal tract is also supported by the detection of Reactive Yellow F68072-vinyl in blood, although the concentrations present at the 4-hour sampling point selected for analysis were low.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.